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Abstract
Hepcidin is a regulatory hormone that plays a major role in controlling body iron homeostasis. Circulating factors
(holotransferrin, cytokines, erythroid regulators) might variably contribute to hepcidin modulation in different pathological
conditions. There are few studies analysing the relationship between hepcidin transcript and related protein expression
profiles in humans. Our aims were: a. to measure hepcidin expression at either hepatic, serum and urinary level in three
paradigmatic iron overload conditions (hemochromatosis, thalassemia and dysmetabolic iron overload syndrome) and in
controls; b. to measure mRNA hepcidin expression in two different hepatic cell lines (HepG2 and Huh-7) exposed to patients
and controls sera to assess whether circulating factors could influence hepcidin transcription in different pathological
conditions. Our findings suggest that hepcidin assays reflect hepatic hepcidin production, but also indicate that correlation
is not ideal, likely due to methodological limits and to several post-trascriptional events. In vitro study showed that THAL
sera down-regulated, HFE-HH and C-NAFLD sera up-regulated hepcidin synthesis. HAMP mRNA expression in Huh-7 cells
exposed to sera form C-Donors, HFE-HH and THAL reproduced, at lower level, the results observed in HepG2, suggesting the
important but not critical role of HFE in hepcidin regulation.
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Introduction
Hepcidin (*606464) is a regulatory hormone that plays a major
role in controlling body iron homeostasis. It is mainly synthesised
in hepatocytes and secreted in the blood as a mature 25-aa peptide
which binds to ferroportin (*604653), the only known cellular iron
exporter, causing ferroportin internalization and degradation and,
in turn, inhibition of iron absorption by enterocytes and iron
release from macrophages [1,2]. Inadequate hepcidin production
relative to body iron stores results in increased iron absorption and
may lead to iron overload. Hepcidin production is mainly
regulated at transcriptional level by several signalling pathways
[1]. Thalassemia syndromes (OMIM#613985) and other anemias
with ineffective erythropoiesis are characterised by marked
reduction of hepcidin synthesis caused by a still unidentified
erythroid signal [3,4]. Hereditary defects of the proteins involved
in hepcidin regulatory pathways are responsible for the different
forms of Hereditary Hemochromatosis (HH, OMIM#235200)
[1,5]. Among them, HH type 1 is the most common in Caucasian
population and is caused by the presence of homozygous p.C282Y
mutation in HFE (HFE-HH, *613609). This leads to the lack of
protein expression on hepatocyte cell membrane, inability to
interact with transferrin receptor (TFR) 1 (*190010) and 2
(*604720) and reduced efficiency in activating hepcidin signalling
[6]. A peculiar, but very common iron overload disorder is the
Dysmetabolic Iron Overload Syndrome (DIOS) which is charac-
terized by mild to moderate iron overload in association with
obesity and alterations of lipid or glucose metabolism, insulin
resistance and Non Alcoholic Fatty Liver Disease (NAFLD) [7].
The mechanism of iron overload in DIOS is still undefined.
Recently, it was shown that hepcidin at either mRNA [8], serum
[9] or urinary [8,9] level is increased in DIOS as compared to
controls, although it was apparently inadequate compared to the
amount of body iron stores. In addition, discrepancies (lack of
correlation) between mRNA expression and urinary hepcidin level
[8] and between serum and urinary hepcidin levels [9] have been
reported in these patients, differently from what observed in
patients with HH [8] and with non-HH-related hepatic cirrhosis
[10]. It has been suggested that inflammatory-dependent cytokines
activation, extrahepatic hepcidin production by adipose tissue as
well as post-translational modifications, or abnormal interaction
with ferroportin at the target sites might be involved in causing
high hepcidin levels in DIOS [11]. Since the discovery of hepcidin
and the demonstration of its pivotal role in iron homeostasis, there
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has been a great interest in measuring this hormone in tissues and
biological fluids to improve our understanding of iron-related
diseases, including DIOS. To our knowledge, data comparing
mRNA, serum or urinary hepcidin levels in humans are scanty.
So, we collected patients with three emblematic iron overload
conditions, e.g. HFE-related HH, thalassemia major and DIOS to
measure hepcidin expression at either mRNA, serum or urinary
level compared to controls. Second, based on the hypothesis that
circulating factors might variably contribute to hepcidin modula-
tion in different pathological conditions, we performed in vitro
studies to evaluate the effects of sera of patients and controls on
hepcidin transcription in two different hepatic cell lines.
Materials and Methods
Patients
Seventy-nine patients including 23 with HFE-hemochromatosis
(HFE-HH), 47 with DIOS, and 9 with b-thalassemia major
(THAL) were enrolled in the study. Control groups consist of: a. 15
patients with non-alcoholic fatty liver disease (NAFLD) without
iron overload which were taken as controls (C-NAFLD) for
evaluating both hepatic mRNA and serum hepcidin levels; b. 28
healthy blood donors at their first donation which were taken as
controls (C-Donors) for serum hepcidin levels and for in vitro study.
General exclusion criteria were: HBV or HCV infection,
autoimmune hepatitis, alpha1-antitrypsin deficiency or Wilson’s
disease; alcohol intake .40 g/day in men and .20 g/day in
women. HFE-HH patients were untreated p.C282Y homozygotes
with increased serum iron indices. Diagnosis of DIOS was based
on the presence of hepatic iron overload with one or more
component of the metabolic syndrome (according to NCEP-
ATPIII criteria) [12]. In this group of patients we excluded the
presence of other known causes of iron overload: history of blood
transfusions or treatment with parenteral iron; HH type I and IV
(OMIM#606069) by genotyping HFE for p.C282Y and p.H63D
variants and by sequencing SLC40A1 (Gene ID: 30061). HH type
II (OMIM#613313 and #602390) and III (OMIM#604250),
iron loading anemias, acute and chronic inflammatory disorders,
chronic hepatic diseases, end-stage liver disease, porphyria cutanea
tarda and aceruloplasminemia were excluded on clinical, bio-
chemical and hepatic histological grounds. All DIOS patients
carried the HFE wild-type genotype but two were heterozygous for
p.H63D. Liver biopsy was performed in 67 patients (14 with HFE-
HH, 47 with DIOS and 6 with THAL) and in 15 controls with
NAFLD for diagnostic or prognostic purposes. 30 of 47 DIOS
patients (64%) had NAFLD defined by the presence of at least 5%
steatosis in liver biopsy [13]. The fifteen controls with NAFLD had
no hepatic iron overload (Deugnier score ,6) and absent or
minimal fibrosis at liver biopsy.
The study, including the overall plan and the informed consent
form was reviewed and approved by the institutional review
boards of San Gerardo Hospital in Monza. All patients had given
written informed consent to genetic testing analysis and liver
biopsy before enrolment in the study according to the Ethical
Committee of our Institution.
Methods
Biochemical indices were measured at the time of diagnosis or
time of liver biopsy (when performed) in HFE-HH, DIOS and in
C-NAFLD, at the time of first donation in C-Donors, and at the
time of liver biopsy in THAL. Body mass index (BMI), blood
pressure and alcohol intake were also measured at diagnosis.
Iron and other biochemical indices. Serum iron,
transferrin and ferritin, serum glucose, total cholesterol, HDL,
triglycerides, alanine-aminotransferases, and c-glutamyl
transferase were measured by standard methods. Transferrin
saturation was calculated as follows {serum iron (mg/dl)/
[transferrin (mg/dl)x1.41]}. Serum IL-6 (*147620) was measured
by ELISA assay (R&D Systems Inc. MN, USA).
Hepcidin in serum and urine. Urinary hepcidin
concentration was assessed in 8 C-NAFLD, 28 DIOS and 15
HFE-HH patients. Urine were collected in the morning, fasting,
just before liver biopsy, preserved with 0.05% sodium azide and
stored at 280uC until measurement. Urinary hepcidin
immunodot assay was performed as previously described [14].
Urinary hepcidin was normalized to urinary creatinine
concentration (ng hepcidin/mg creatinine). Quantification of
serum hepcidin-25 was performed in 47 DIOS, 21 HFE-HH
and 8 THAL patients, as well as in 15 C-NAFLD and 24 C-
Donors. After collection, sera were stored at 280uC until
measurement. Serum hepcidin-25 levels were determined by
liquid chromatography–tandem mass spectrometry (LC/MS/
MS)-based assay as reported [15,16]. Intra-assay and inter-assay
coefficients of variation (CVs) were less than 6.7 and less than
8.8%, respectively. The lower limit of detection was 1.0 ng/mL
with a signal to noise ratio of 10:1 [17].
Liver biopsy. Immediately after the procedure, the biopsy
was cut into two pieces. A 2.5 cm piece was fixed in 10% formalin
(pH 7.4) for histology, whereas a 0.5–1 cm of tissue from needle
liver biopsy was snap-frozen in liquid nitrogen for mRNA analysis.
Hepatic sections were stained with standard and Perls’ staining for
routine histology and iron deposition, respectively. Grading and
staging were classified as described by Ishak et al [18], and
steatosis by Kleiner’s score [13]. Liver iron overload was assessed
as described by Deugnier et al [19], with Hepatocyte Iron Score
(HIS) ranging from 0 to 36, Sinusoidal Iron Score (SIS) from 0 to
12, and Portal Iron Score (PIS) from 0 to 12. The sum of HIS, SIS
and PIS is the Total Iron Score (TIS) which ranges from 0 to 60.
RNA extraction and cDNA synthesis. RNA from hepatic
tissue was extracted using TRIzol (Invitrogen, Grand Island, NY,
USA) according to the manufacturer’s protocol, quantified by
spectrophotometry and its integrity assessed by nondenaturing
agarose gel. 2 mg of total RNA was used as a template for reverse
transcription, performed using the High Capacity cDNA Archive
kit (Applera, Foster City, CA, USA), according to the
manufacturer’s protocol.
Real-time quantitative-PCR. mRNA expression levels of
HAMP (Gene ID:57817) were evaluated by quantitative real time
PCR (qRT-PCR); HPRT1 (Gene ID:3251) was chosen as
housekeeping gene. The analysis were performed on an ABI
7900HT (Applera, Foster City, CA, USA) using the Assays-on-
Demand Gene Expression Products (Applera) according to the
manufacture’s protocol (catalog no. of TaqMan AssayH are
Hs99999909_m1 and Hs00221783_m1 for HPRT1 and HAMP,
respectively). Instrument was set up with default thermal cycler
protocol provided by the producer: 50uC for 2 min, 95uC for
10 min, 95uC for 15sec and 60uC for 1 min for 40 cycles.
TaqManH Assays (20X) contain 18 mM of each primers and 5 mM
for the probe. Amplification efficiencies were calculated according
to our experimental conditions and were found to be 96% for
HAMP and 98% for HPRT1, data in accordance with the
TaqManH Gene Expression Assays datasheet that reports a PCR
efficiency of 100% (610%). Inter-assay plate variation showed a %
Coefficient of Variation (CV) of 1.17% and 1.21% for hepatic
HAMP and HPRT1, respectively, in three different liver samples;
%CV for cellular HAMP was 0.80% and 1.9% for cellular HPRT1
in three different HepG2 and Huh-7 samples. For each PCR
reaction, 15 ng of cDNA were used as a template. All analyses
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were carried out in triplicate; results showing a discrepancy greater
than 0.3 cycle between the samples were excluded. Relative
quantities present in each sample were assessed using the 22(DDCt)
method [20]; a cDNA generated from total liver RNA (Invitrogen,
Grand Island, NY, USA) was used as external control. Non-
retrotranscribed RNAs were included in each amplification plate,
and the analysis regarded as valid if the fluorescence intensity in
the no-template control was zero.
In vitro study. The human hepatoma HepG2 cell-line was
grown in MEM (Minimum Essential Medium) supplemented with
10% heat-inactivated fetal bovin serum (FBS), glutamine and
combined antibiotics, 37uC e 5% CO2. The human hepatoma
Huh-7 cell-line was grown in DMEM (Dulbecco Modified
Essential Medium) in the same conditions. For the examination
of serum effect, cells were seeded in 6-well plates (300.000 cell/
well). After 24 h they were starved of FBS for 24 h, after which the
medium was changed to medium containing 10% human serum
[21]. After an additional 48 h, the cells were harvested for RNA
isolation and gene expression analysis as reported above. We
treated HepG2 cells with sera of 13 HFE-HH, 28 DIOS, 9 THAL
patients and 13 C-NAFLD and 28 C-Donors. Huh-7 were
incubated with sera of 13 HFE-HH, 9 THAL patients and 28 C-
Donors. Cell lines were bought from I.Z.S.L.E.R. (Istituto
Zooprofilattico Sperimentale della Lombardia e dell’Emilia-
Romagna, Brescia, Italy).
Statistical analysis. Data were expressed as median and
range. All comparisons involving quantitative variables were
performed by nonparametric tests: Kruskal-Wallis with Dunn’s
test for multiple comparisons, and Mann–Whitney to compare two
groups of patients. The degree of linear association between two
variables was assessed by Spearman’s test. All tests were two sided
and with a significance level of a equal to 0.05. Analyses were
carried out by the GRAPHPAD PRISM statistical analysis
software (version 3.02) (GraphPad Software, Inc., La Jolla, CA,
USA).
Results
Subjects characteristics are shown in Table 1. Excluding THAL
patients, age, total cholesterol, cGT, serum glucose and hemo-
globin concentration did not differ among groups.
Iron and metabolic indices significantly differed among groups.
As expected, HFE-HH and THAL had more severe iron overload
than other groups, whereas DIOS and C-NAFLD had more
metabolic abnormalities and steatosis than HFE-HH and THAL.
To evaluate the possible effect of inflammatory activation on
hepcidin levels in patients with dysmetabolic alterations, we
measured IL-6 concentrations in DIOS and C-NAFLD compared
to C-Donors. Serum IL-6 was higher in C-NAFLD [0.99 (0.16–
21.35) pg/ml] than in DIOS [0.10 (0.10–7.010) pg/ml] and C-
Donors [0.10 (0.10–4.52) pg/ml] (p,0.001).
mRNA, Serum and Urinary Hepcidin
HFE-HH and THAL had the lowest mRNA, serum and urinary
hepcidin among groups, whereas DIOS had the highest (Table 2).
The correction of hepcidin values for the amount of storage iron
(serum ferritin and TIS) underscores the inadequate production of
hepcidin in HFE-HH and THAL, and the higher values in C-
NAFLD and DIOS in the order (Table 3).
Correlation between Hepcidin Levels and Other Variables
Serum and urinary hepcidin showed a significant correlation in
the whole population (r:0.62, p,0.0001) and in HFE-HH patients
(r:0.54, p = 0.037). In the whole population, HAMP mRNA level
correlated with serum and with urinary hepcidin concentration
(r:0.32, p = 0.0057 and r:0.34, p = 0.025 respectively). Serum
hepcidin also inversely correlated with transferrin saturation (r:-
0.25, p= 0.014) in the whole population, but not in single groups.
In the whole population (r:0.241, p= 0.013) there was a direct
correlation between serum ferritin and serum hepcidin concen-
tration, as also observed in the DIOS (r:0.38, p = 0.0082), C-
Donors (r:0.837, p,0.0001) and C-NAFLD (r:0.552, p= 0.033)
groups.
HAMP mRNA Response to Patient’s Sera in HepG2 and
Huh-7 Cell Lines
Differently to HepG2, Huh-7 carries a mutation in HFE leading
to the lack of HFE expression on the cell membrane [22], thus
being a good in vitro model for testing whether the absence of this
protein causes a different regulation of hepcidin expression after
incubation with human serum. As reported in Table 4, treatment
of HepG2 cells with the sera of C-NAFLD and HFE-HH
increased hepcidin mRNA synthesis whereas exposure to THAL
sera induced a strong inhibition. By contrast, treatment of HepG2
cells with DIOS sera did not induce significant differences in
hepcidin expression compared to C-Donors. Similar results were
obtained in Huh-7 exposed to C-Donors, HFE-HH and THAL
sera, although HAMP expression was significantly lower than in
HepG2 cells in each group (Table 4). HAMP mRNA levels in
HepG2 and Huh-7 significantly correlated (r:0.625, p,0.0001)
when the whole population was considered.
Discussion
Our study provides some new and some confirmatory findings.
First, quantification of hepcidin indicated that the amount of
protein in serum and urine significantly but slightly correlated with
the liver transcript in the whole population. Second, among
patients with iron overload, hepcidin expression was up-regulated
in DIOS and patients with NAFLD without iron overload (C-
NAFLD) and down-regulated in HFE-HH and THAL. Third,
incubation of hepatic cell lines with patients’ sera showed that
circulating factors can variably modulate hepcidin expression.
There are few studies analysing the relationship between
hepcidin transcript and related protein expression profiles in
humans. Detivaud et al [10] and Kattamis et al [23] found
a moderate correlation between urinary hepcidin and mRNA
transcript in patients with chronic liver disease and thalassemia,
but such correlation was not found in DIOS patients [8]. When
patients with chronic hepatitis C were evaluated, Tsochatzis et al
[24] found no correlation whereas Fujita et al [25] showed a nice
correlation between HAMP hepatic transcript and serum hepcidin.
The results reported in the present manuscript extend the
observation to a large number of patients with different hepatic
disorders. Overall, these findings suggest that hepcidin assays
reflect hepatic hepcidin production, but also indicate that this
correlation is not ideal. This fact is possibly due to limits in
quantitative accuracy of hepcidin mRNA and protein measure-
ments, but also to several post-trascriptional events (protein
degradation and secretion, hepcidin-ferroportin interaction and
hepcidin internalization at its target sites, and extra-hepatic
production) which might have a role in determining the net
amount of circulating and functional protein. Although hepcidin is
mainly expressed in hepatocytes, it is also expressed in other
organs including heart, lung, adipose and macrophage-rich tissues,
whose contribution to the amount of circulating hepcidin is
unknown and might vary in different pathological conditions [1].
Hepcidin in Iron Overload Diseases
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Second, our results confirm that DIOS patients retain the ability
to increase hepcidin production in response to iron load,
differently to HFE-HH and THAL. It cannot be excluded that
mild inflammation [shown by the slightly higher IL-6 levels than in
healthy controls] might contribute to the increased hepcidin
production. However, we previously demonstrated that iron
depletion normalized hepcidin levels in DIOS, indicating that
iron stores were major determinants of hepcidin increase [26].
This also explains some of the phenotypic characteristics of the
syndrome: normal transferrin saturation, increased iron accumu-
lation in macrophages and absence of progression of iron overload
[9,27,28]. These results are even more evident when considering
the ratios between hepcidin and ferritin or TIS at both the mRNA
and protein levels. The correction of hepcidin data according to
serum ferritin level is supposed to better assess the adequateness of
hepcidin production to the stimulus induced by iron overload
because of the strong correlation between hepcidin and ferritin
concentrations [29]. However, this ratio should be taken with
caution when considering disorders characterized by serum ferritin
increase disproportionate to the amount of iron overload such as
C-NAFLD and DIOS [30,31], due to hepatocellular necrosis and
local inflammation. Taking TIS as a measure of hepatic iron
overload, we showed that C-NAFLD had the highest ratio among
groups at each level (serum, urinary and mRNA), from 2.5 to 4
times higher than DIOS, and that DIOS had 5 or more times
higher ratios than HFE-HH and THAL. The higher serum IL-6 in
C-NAFLD likely explain the higher hepcidin/TIS ratio compared
to DIOS patients.
Hepcidin transcription is modulated by different stimuli, which
act as positive or negative regulators. There are four main active
Table 1. Characteristics of the subjects.
C-Donors (n=28) C-NAFLD (n=15) DIOS (n=47) HFE-HH (n=23) THAL (n=9)
Age (yrs) 45 (19–60) 42 (21–66) 55 (30–68) 41 (21–68) 30 (27–37)
BMI (Kg/m2) 24.1 (21–27.5) 26.3 (23–39.7) 25.4 (22–33.6) 24.2 (18.8–28) 23.9 (18.8–27.8)
Alcohol (g/day) 5 (0–30) 0 (0–40) 7.5 (0–30) 10 (0–60) 5 (0–40)
Hemoglobin (gr/dL) 14.3 (13.5–16) 15.0 (13.3–16.9) 14.2 (11.2–16.3) 14.6 (11.2–16.8) 9.8 (8.3–10.7)
Transferrin Saturation (%) 29 (20–41) 32.5 (21–222) 38 (9–65) 87 (3.2–98) 97 (94–106)
Ferritin (mg/L) 71 (53–308) 241 (41–806) 872 (351–2293) 1392 (201–4728) 1060 (520–2481)
TIS ND 0 (0–6) 17 (12–29) 32* (22–38) 27.5u (16–37)
Glucose (mg/dL) 92 (64–101) 101 (73–203) 95 (75–146) 96 (65–131) 111 (93–189)
Cholesterol (mg/dL) 199 (137–266) 180 (112–227) 197.5 (125–273) 198 (145–256) 114 (62–166)
Triglycerides (mg/dL) 80 (42–133) 109 (34–233) 119.5 (61–505) 93 (57–180) 82 (45–346)
Steatosis (%) ND 60 (0–98) 65 (0–98) 0 (0–70) 0 (0–0)
ALT (IU/L) 21.5 (14–38) 60 (33–103) 39 (17–118) 32.5 (12–67) 34 (12–95)
cGT (IU/L) ND 51 (16–109) 39.5 (16–271) 30 (11–350) 20.5 (14–57)
Values are represented as median (range).
ND: not done; ALT: alanine aminotransferase; c-GT: c-glutamyl-transferase; TIS: Total Iron Score; *: available in 14 patients; u: available in 6 patients.
Age: DIOS vs THAL (p,0.01);
BMI: C-NAFLD vs C-Donors, HFE-HH, THAL (p,0.05);
Hemoglobin: THAL vs all (p,0.01);
Transferrin saturation: C-Donors vs HFE-HH, THAL (p,0.01); C-NAFLD vs HFE-HH, THAL (p,0.01); DIOS vs HFE-HH, THAL (p,0.01);
Ferritin: C-NAFLD vs DIOS, HFE-HH, THAL (p,0.01);
TIS: C-NAFLD vs all (p,0.01); DIOS vs HFE-HH (p,0.01);
Cholesterol: THAL vs C-Donors, DIOS, HFE-HH (P,0.05);
Tryglicerides: C-Donors vs DIOS (p,0.01);
Steatosis: C-NAFLD vs HFE-HH, THAL (p,0.01); DIOS vs HFE-HH, THAL (p,0.01);
ALT: C-Donors vs NAFLD, DIOS (p,0.01); C-NAFLD vs HFE-HH (p,0.05).
doi:10.1371/journal.pone.0036425.t001
Table 2. Levels of HAMP mRNA, serum and urinary hepcidin in controls (NAFLD patients without iron overload), DIOS and HFE-HH
patients.
C-Donors C-NAFLD DIOS HFE-HH THAL
HAMP mRNA (22DDCt) ND (N=15) 32.9 (3.6–52) (N = 47) 44.6 (12.6–187.3) (N = 14) 18.5 (3.9–56.8) (N = 6) 13.8 (3.9–41.8)
S-Hepcidin (ng/mL) (N = 24) 14 (3.3–36.5) (N = 15) 11.1 (0.5–25.5) (N = 47) 17.4 (2.1–65.0) (N = 21) 4.8 (1.0–31.3) (N = 8) 6.15 (2.3–38.5)
U-Hepcidin (ng/mg creatinine) ND (N=8) 82 (30–156) (N = 28) 163 (72–449) (N = 15) 24 (2–169) ND
Values are represented as median (range).
ND: not done.
HAMP mRNA: DIOS vs HFE-HH, THAL (p,0.01);
S-Hepcidin: HFE-HH vs C-Donors, DIOS (p,0.01); NAFLD vs DIOS (p,0.05);
U-Hepcidin: DIOS vs HFE-HH (p,0.01), NAFLD (p,0.05).
doi:10.1371/journal.pone.0036425.t002
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regulatory pathways (erythroid-, inflammatory-, iron- and hypox-
ia-mediated) which control hepcidin production through different
signalling pathways [1,2,4]. Some of them are activated by factors
circulating in blood: a. holotransferrin stimulates hepcidin
synthesis interacting with the iron sensor complex (formed by
TFR1 and 2, and HFE) at hepatocyte membrane; b. IL-6 induces
hepcidin synthesis through IL-6 receptor (Gene ID: 3570) and
STAT3 (Gene ID: 6764) signalling; c. factor(s) released by
erythroblasts likely regulate the transcription of hepcidin in the
liver according to erythropoiesis activation [32]. We then analysed
modulation of HAMP mRNA expression induced by incubating
two different hepatic cell lines (HepG2 and Huh-7) with patients’
sera. Our results indicate that: a. sera of patients with THAL
down-regulated hepcidin synthesis as previously reported [33]; b.
HFE-HH and C-NAFLD sera induced HAMP transcription; c.
serum of patients with DIOS did not lead to significant changes as
compared to C-Donors; d. HAMP mRNA expression in Huh-7
cells exposed to sera form C-Donors, HFE-HH and THAL
reproduced the results observed with HepG2, but at lower level.
These results allow the following conclusions to be made. First,
hepcidin down-regulation induced by THAL sera confirms the
existence of regulating factor(s) released by erythroblasts into the
plasma to modulate hepcidin production [21,34]. It was suggested
a role for GDF15 (*605312) and TWSG1 (*605049) erythropoietic
growth factors [35], but recent studies challenged the hypothesis,
suggesting that other erythroid factors might be implicated
[36,37]. Hepcidin down-regulation occurred in HepG2 cells
treated with THAL sera despite their high transferrin saturation
which was supposed to increase hepcidin synthesis. This indicates
that the hepcidin regulatory pathway triggered by the putative
erythroid factor(s) predominates on the signalling cascade
activated by diferric holotransferrin. The latter likely explains
the increased hepcidin transcription observed when HepG2 cells,
which have a normal HFE, were incubated with the iron
overloaded serum of HFE-HH patients. DIOS sera did not induce
any differences in hepcidin production as compared to C-Donors.
This finding suggests that the slight increase of IL-6 level was not
sufficient to induce hepcidin expression in vitro and further
confirms that the increased mRNA and protein hepcidin levels
observed in patients with DIOS mainly depend to the increased
liver iron storage. By contrast, exposure of HepG2 cells with the
serum of C-NAFLD patients led to the highest up-regulation of
hepcidin mRNA among groups analyzed. Circulating inflamma-
tory cytokines, as shown by the higher IL-6 levels compared to that
observed in DIOS and C-Donors, were likely major determinants
of hepcidin up-regulation in HepG2 cells induced by C-NAFLD
Table 3. Ratios of HAMP mRNA, serum and urinary hepcidin in controls (NAFLD patients without iron overload), DIOS and HFE-HH
patients.
C-Donors C-NAFLD DIOS HFE-HH THAL
Normalized HAMP mRNA ND N=15 N=47 N=14 N=6
HAMP/SF ND 0.11 (0.02–1.17) 0.05 (0.01–0.16) 0.01 (0.00–0.05) 0.01 (0.00–0.03)
HAMP/TIS ND 8 (5.1–47.2) 3.01 (0.6–6.9) 0.43 (0.1–1.9) 0.53 (0.2–1.5)
Normalized S-hepcidin N=24 N=15 N=47 N=21 N=8
S-hepcidin/SF 0.11 (0.06–0.25) 0.03 (0.00–0.27) 0.02 (0.00–0.05) 0.00 (0.00–0.02) 0.00 (0.00–0.01)
S-hepcidin/TIS ND 2.48 (1.5–12.8) 1.07 (0.15–2.9) 0.16 (0.05–0.9) 0.27 (0.14–0.9)
Normalized
U-hepcidin
ND N=8 N=28 N=15 ND
U-hepcidin/SF ND 0.60 (0.08–1.51) 0.19 (0.05–0.72) 0.05 (0.00–0.10) ND
U-hepcidin/TIS ND 40.5 (5.0–76.0) 10 (4.5–36.2) 2.12 (0.00–7.3) ND
Values are represented as median (range).
ND: not done; SF: serum ferritin; TIS: Total Iron Score.
HAMP/SF: NAFLD vs HFE-HH, THAL (p,0.01) DIOS (p,0.05); DIOS vs HFE-HH (p,0.01), THAL (p,0.05);
HAMP/TIS: C-NAFLD vs HFE-HH, THAL (p,0.01); DIOS vs HFE-HH, THAL (p,0.01);
S-hepcidin/SF: C-Donors vs DIOS, HFE-HH, THAL (p,0.01); NAFLD vs HFE-HH (p,0.01), THAL (p,0.05); DIOS vs HFE-HH (p,0.01);
S-hepcidin/TIS: NAFLD vs HFE-HH, THAL (p,0.01); DIOS vs HFE-HH (p,0.01);
U-hepcidin/SF: HFE-HH vs DIOS, NAFLD (p,0.01);
U-hepcidin/TIS: DIOS vs HFE-HH (p,0.01).
doi:10.1371/journal.pone.0036425.t003
Table 4. HAMP mRNA expression in HepG2 and Huh-7 cells treated with different patients sera.
C-Donors (n =28) C-NAFLD (n=13) DIOS (n=28) HFE-HH (n=13) THAL (n =9)
HepG2 HAMP mRNA (22DDCt) 2.06 (0.6–4.8) 6.34 (0.6–16.5) 2.32 (0.3–6.7) 4.13 (1.5–12.5) 0.44 (0.1–1.4)
Huh-7 HAMP mRNA (22DDCt) 1.25 (0.3–2.2) ND ND 2.34 (0.6–4.1) 0.12 (0.03–0.5)
p (HepG2 vs Huh-7) 0.003 – – 0.022 0.005
Results are expressed as 22DDCt, as median (range).
ND: not done.
HepG2 HAMP mRNA: THAL vs all (p,0.01); HFE-HH vs C-Donors (p,0.05); C-NAFLD vs C-Donors (p,0.01); C-NAFLD vs DIOS (p,0.02);
Huh-7 HAMP mRNA: THAL vs all (p,0.01); HFE-HH vs C-Donors (p,0.01).
doi:10.1371/journal.pone.0036425.t004
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sera. The results observed in Huh-7 cell lines support the role of
HFE as hepatocyte iron sensor in modulating hepcidin synthesis
through interaction with diferric holotransferrin, TFR21 and 22
[6] in healthy controls, HFE-HH and THAL patients. Neverthe-
less, hepcidin response of Huh-7 cell lines to HFE-HH sera
suggests that HFE has an important but not critical role in
regulating HAMP transcription and that other components of the
membrane iron sensor complex may activate hepcidin signalling
even in the absence of HFE. This might explain the low
penetrance of the p.C282Y homozygous genotype and support
the idea that full expression of HH type 1 requires additional
factors either genetic or acquired.
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